Esophageal carcinoma (squamous + adeno) · line 1 · Nivolumab adjuvant — post-CROSS without pCR (CheckMate-577)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy	1
Track	aggressive
Linked regimen	`REG-NIVO-ADJUVANT-ESOPH`

ID	`IND-ESOPH-ADJUVANT-NIVOLUMAB-POST-CROSS`
Type	Indication
Status	reviewed 2026-04-26 \| pending_clinical_signoff
Diseases	`DIS-ESOPHAGEAL`
Sources	`SRC-ESMO-ESOPHAGEAL-2024` `SRC-NCCN-ESOPHAGEAL-2025`

Notes

Adjuvant indication — follows IND-ESOPH-RESECTABLE-CROSS-NEOADJUVANT when post-resection pathology shows residual disease.

Used By

Algorithms

ALGO-ESOPH-RESECTABLE-1L - ALGO-ESOPH-RESECTABLE-1L
ALGO-ESOPHAGEAL-ADJUVANT-1L - ALGO-ESOPHAGEAL-ADJUVANT-1L

Red flag

RF-ESOPHAGEAL-POST-CROSS-NON-PCR - Post-CROSS-CRT-then-esophagectomy with residual disease — pathology shows ypT+ and/or ypN...